Business Standard

Thursday, January 09, 2025 | 03:33 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cadila Healthcare's Baddi unit receives 3 observations under Form 483

Observations, given by US FDA, are related to pre-approval inspection for a specific product filed

Cadila Healthcare’s Baddi unit receives 3 observations under Form 483
Premium

BS B2B Bureau Mumbai
Following an inspection by the US Food & Drug Administration (FDA) from February 20, 2017 to March 1, 201, Cadila Healthcare’s formulations manufacturing facility at Baddi (Himachal Pradesh) has received three observations given under Form 483 from the US dug regulator. All these three observations are related to pre-approval inspection (PAI) for a specific product filed.

“This product is yet to be manufactured or marketed in the US. The company is already in the process of responding to the PAI observations. Apart from above product related observations, there are no observations related to cGMP practices,” said the company in a BSE

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in